In patients with type 2 diabetes
with high CV risk
with high CV risk
CV DEATH
HAS A
NEW OPPONENT
Jardiance® (Empagliflozin) is the only type 2 diabetes pill proven to go beyond lowering A1C to reduce the risk of CV death for adults who have type 2 diabetes and heart disease
Global clinical guidelines recommendation for the preferential use of SGLT2 inhibitors in patients with T2D and CKD
Document ID: PC-AE-101744
24/04/2023
Author: Boehringer Ingelheim
Global clinical guidelines recommendation for the preferential use of SGLT2 inhibitors in patients with T2D and CKD
123,000
Views
100k 340
Related content
PC-AE-101744
Production date: April 2023
Production date: April 2023
